Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Dysregulated bile acid (BA) synthesis or reduced farnesoid X receptor (FXR) levels are found in patients having metabolic diseases, autoimmune hepatitis, and liver cirrhosis or cancer. The objective of this study was to establish the relationship between butyrate and dysregulated BA synthesis‐induced hepatitis as well as the effect of butyrate in reversing the liver pathology. Wild‐type (WT) and FXR knockout (KO) male mice were placed on a control (CD) or western diet (WD) for 15 months. In the presence or absence of butyrate supplementation, feces obtained from 15‐month‐old WD‐fed FXR KO mice, which had severe hepatitis and liver tumors, were transplanted to 7‐month‐old WD‐fed FXR KO for 3 months. Hepatic phenotypes, microbiota profile, and BA composition were analyzed. Butyrate‐generating bacteria and colonic butyrate concentration were reduced due to FXR inactivation and further reduced by WD intake. In addition, WD‐fed FXR KO male mice had the highest concentration of hepatic β‐muricholic acid (β‐MCA) and bacteria‐generated deoxycholic acid (DCA) accompanied by serious hepatitis. Moreover, dysregulated BA and reduced SCFA signaling co‐existed in both human liver cancers and WD‐fed FXR KO mice. Microbiota transplantation using butyrate‐deficient feces derived from 15‐month‐old WD‐fed FXR KO mice increased hepatic lymphocyte numbers as well as hepatic β‐MCA and DCA concentrations. Furthermore, butyrate supplementation reduced hepatic β‐MCA as well as DCA and eliminated hepatic lymphocyte infiltration. In conclusion, reduced butyrate contributes to the development of hepatitis in the FXR KO mouse model. In addition, butyrate reverses dysregulated BA synthesis and its associated hepatitis. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
den Besten, G., van Eunen, K., Groen, A. K., Venema, K., Reijngoud, D.-J., & Bakker, B. M. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r036012 · Cited by 5,048
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
Gevers, D., Kugathasan, S., Denson, L. A., Vázquez-Baeza, Y., Van Treuren, W., Ren, B., Schwager, E., Knights, D., Song, S. J., Yassour, M., et al. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.005 · Cited by 3,220
Short-chain fatty acids in control of body weight and insulin sensitivity
Canfora, E. E., Jocken, J. W., & Blaak, E. E. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.128 · Cited by 2,298 · cited 9×
“Among the SCFAs, butyrate has an apparent histone deacetylase (HDAC) inhibitory property that is used to combat cancer [25,26].”
BackgroundInfluentialObesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
Yoshimoto, S., Loo, T. M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H., Hattori, M., et al. (2013) · Nature · doi:10.1038/nature12347 · Cited by 2,219
Butyrate improves insulin sensitivity and increases energy expenditure in mice
Gao, Z., Yin, J., Zhang, J., Ward, R. E., Martin, R. J., Lefevre, M., Cefalu, W. T., & Ye, J. (2009) · Diabetes · doi:10.2337/db08-1637 · Cited by 2,204 · cited 1×
“Furthermore, butyrate activates p38, which may contribute to increased PGC-1α activity [49,50].”
BackgroundDietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice
Devkota, S., Wang, Y., Musch, M. W., Leone, V., Fehlner-Peach, H., Nadimpalli, A., Antonopoulos, D. A., Jabri, B., & Chang, E. B. (2012) · Nature · doi:10.1038/nature11225 · Cited by 1,904
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819 · cited 1×
“C57BL/6 wild-type (WT) (Jackson Laboratory, Sacramento, CA, USA) and whole body FXR KO male mice [29] were given a WD (21% fat, 34% sucrose, and 0.”
MethodRole of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
Inhibition of Histone Deacetylase Activity by Butyrate
Davie, J. R. (2003) · The Journal of Nutrition · doi:10.1093/jn/133.7.2485s · Cited by 1,515
Potential beneficial effects of butyrate in intestinal and extraintestinal diseases
Canani, R. B. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i12.1519 · Cited by 1,381
Research works printed but not linked: 38
- 10.1097/MOG.0000000000000156 · DOI · Paper page
- 10.1016/j.jhep.2015.08.001 · DOI · Paper page
- 10.1210/me.2011-1383 · DOI
- 10.1152/ajpgi.00439.2011 · DOI · Paper page
- 10.1210/me.2011-1157 · DOI · Paper page
- 10.1016/j.taap.2013.06.016 · DOI
- 10.1124/jpet.111.179390 · DOI
- 10.1152/ajpgi.00134.2015 · DOI
- 10.1016/j.jhep.2015.09.022 · DOI · Paper page
- 10.1038/aps.2014.117 · DOI
- 10.1007/s11095-013-0986-7 · DOI · Paper page
- 10.1621/nrs.08005 · DOI · Paper page
- 10.1136/gutjnl-2015-310283 · DOI · Paper page
- 10.1177/1535370214538743 · DOI · Paper page
- 10.1158/2159-8290.CD-14-0501 · DOI · Paper page
- 10.1007/s10555-015-9578-9 · DOI
- 10.1194/jlr.D028803 · DOI · Paper page
- 10.18632/oncotarget.6665 · DOI
- 10.1074/jbc.M114.620369 · DOI
- 10.1021/pr2011507 · DOI · Paper page
- 10.1128/AEM.02561-06 · DOI · Paper page
- 10.1186/s40168-015-0091-8 · DOI · Paper page
- 10.1007/s12032-016-0729-9 · DOI
- 10.1007/s11605-011-1775-4 · doi:10.1007/s11605-011-1775-4
- Wang WW, 2013, Identification of serum monocyte chemoattractant protein‐1 and prolactin as potential tumor markers in hepatocellular carcinoma, PloS One, 8
- 10.1089/ten.tea.2008.0663 · DOI
- 10.1016/j.bone.2009.10.032 · DOI
- 10.4049/jimmunol.174.8.5047 · DOI · Paper page
- 10.1152/ajpcell.2000.278.3.C500 · doi:10.1152/ajpcell.2000.278.3.c500
- 10.1182/blood.V95.7.2391 · DOI · Paper page
- 10.1128/mBio.00889-14 · DOI · Paper page
- 10.1371/journal.pone.0115175 · DOI · Paper page
- 10.1016/j.febslet.2014.11.042 · DOI · Paper page
- 10.1158/1541-7786.MCR-14-0230 · DOI
- 10.1002/hep.24101 · DOI
- 10.1016/0378-4347(92)80091-4 · doi:10.1016/0378-4347(92)80091-4
- 10.1093/toxsci/kfu227 · DOI
- 10.1073/pnas.1518189113 · DOI · Paper page
Cited by
Gut–liver axis: barriers and functional circuits
Pabst, O., Hornef, M. W., Schaap, F. G., Cerovic, V., Clavel, T., & Bruns, T. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00771-6 · Cited by 436
Dietary fat, bile acid metabolism and colorectal cancer
Ocvirk, S., & O’Keefe, S. J. D. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.10.003 · Cited by 262
Lee, P.-C., Wu, C.-J., Hung, Y.-W., Lee, C. J., Chi, C.-T., Lee, I.-C., Yu-Lun, K., Chou, S.-H., Luo, J.-C., Hou, M.-C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004779 · Cited by 217
Ma, J., Hong, Y., Zheng, N., Xie, G., Lyu, Y., Gu, Y., Xi, C., Chen, L., Wu, G., Li, Y., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1763770 · Cited by 171
Self-citationJena, P. K., Sheng, L., Di Lucente, J., Jin, L., Maezawa, I., & Wan, Y. Y. (2018) · The FASEB Journal · doi:10.1096/fj.201700984rr · Cited by 134
Self-citationPromises of microbiome-based therapies
Bajaj, J. S., Ng, S. C., & Schnabl, B. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.003 · Cited by 119
Metadata
- Authors
- Sheng, L., Jena, P. K., Hu, Y., Liu, H., Nagar, N., Kalanetra, K. M., French, S. W., French, S. W., Mills, D. A., & Wan, Y. Y.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2017-11
- Volume
- 243
- Issue
- 4
- Pages
- 431-441
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2754032461
- Cited by
- 133
- References
- 24
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- National Cancer Institute (U01CA179582)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.